{
    "root": "3001d1ed-b200-7d1b-e063-6394a90ab45f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FULVESTRANT",
    "value": "20250310",
    "ingredients": [
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17987"
        },
        {
            "name": "BENZYL BENZOATE",
            "code": "N863NB338G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_41237"
        },
        {
            "name": "CASTOR OIL",
            "code": "D5340Y2I9G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_140618"
        },
        {
            "name": "FULVESTRANT",
            "code": "22X328QOC4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31638"
        }
    ],
    "indications": {
        "text": "monotherapy fulvestrant injection indicated treatment : hormone receptor ( hr ) -positive , human epidermal growth factor receptor 2 ( her2 ) -negative advanced breast cancer postmenopausal women previously treated endocrine therapy , hr-positive advanced breast cancer postmenopausal women disease progression following endocrine therapy . combination therapy fulvestrant injection indicated treatment : hr-positive , her2-negative advanced metastatic breast cancer postmenopausal women combination ribociclib initial endocrine based therapy following disease progression endocrine therapy . hr-positive , her2-negative advanced metastatic breast cancer combination palbociclib abemaciclib women disease progression endocrine therapy .",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "fulvestrant injection 500 mg administered intramuscularly buttocks ( gluteal area ) slowly ( 1 - 2 minutes per injection ) two 5 ml injections , one buttock , days 1 , 15 , 29 , monthly thereafter . ( 2.1 , 14 ) dose 250 mg recommended patients moderate hepatic impairment administered intramuscularly buttock ( gluteal area ) slowly ( 1 - 2 minutes ) one 5 ml injection days 1 , 15 , 29 , monthly thereafter . ( 2.2 , 5.2 , 8.6 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "fulvestrant injection supplied two 5 ml clear glass ( type 1 ) barrels , containing 250 mg/5 ml fulvestrant solution intramuscular injection fitted tamper evident closure . fulvestrant injection clear , colorless yellow , viscous solution . ndc 16729-436-31 two pre-filled syringes containing 250 mg/5 ml fulvestrant solution intramuscular injection two safety needles ( safetyglide\u2122 ) packaged per carton ndc 16729-436-30 single-dose prefilled syringes presented tray polypropylene plunger rod safety needles ( safetyglide\u2122 ) connection barrel . discard syringe . patient dose requires one syringe , unused syringe stored directed . storage : refrigerate , 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) . protect light , store original carton time .",
    "adverseReactions": "fulvestrant injection contraindicated patients known hypersensitivity components . hypersensitivity , including urticaria angioedema , reported association fulvestrant injection [ ( 6.2 ) ] .",
    "indications_original": "Monotherapy\n                     \n                  \n                  Fulvestrant injection is indicated for the treatment of:\n                  \n                     Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or\n                     HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.\n                  \n                  \n                     \n                        Combination Therapy\n                     \n                  \n                  Fulvestrant injection is indicated for the treatment of:\n                  \n                     HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.\n                     HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.",
    "contraindications_original": "Fulvestrant injection 500 mg should be administered intramuscularly into the buttocks (gluteal area) slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter. ( 2.1 , 14 ) A dose of 250 mg is recommended in patients with moderate hepatic impairment to be administered intramuscularly into the buttock (gluteal area) slowly (1 - 2 minutes) as one 5 mL injection on Days 1, 15, 29, and once monthly thereafter. ( 2.2 , 5.2 , 8.6 )",
    "warningsAndPrecautions_original": "Fulvestrant injection is supplied as two 5 mL clear glass (Type 1) barrels, each containing 250 mg/5 mL of Fulvestrant solution for intramuscular injection and fitted with a tamper evident closure. Fulvestrant Injection is a clear, colorless to yellow, viscous solution.\n                  NDC 16729-436-31\n                  Two pre-filled syringes each containing 250 mg/5 mL of Fulvestrant solution for intramuscular injection and two safety needles (SafetyGlide\u2122) are packaged per carton with NDC 16729-436-30\n                  The single-dose prefilled syringes are presented in a tray with polypropylene plunger rod and safety needles (SafetyGlide\u2122) for connection to the barrel.\n                  Discard each syringe after use. If a patient dose requires only one syringe, unused syringe should be stored as directed below.\n                  \n                     Storage:\n                  \n                  REFRIGERATE, 2\u00b0C TO 8\u00b0C (36\u00b0F TO 46\u00b0F).\n \n  TO PROTECT FROM LIGHT, STORE IN THE ORIGINAL CARTON UNTIL TIME OF USE.",
    "adverseReactions_original": "Fulvestrant injection is contraindicated in patients with a known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema, have been reported in association with Fulvestrant injection\n \n  [see\n  \n   Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "FULVESTRANT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31638"
        }
    ]
}